A Phase II Simon Two-Stage Multicenter Study and Pilot Pharmacodynamic Investigation of GTI 2040 in Combination With High Dose Cytarabine (HiDAC) in Refractory and Relapsed Acute Myeloid Leukemia (AML)).

Trial Profile

A Phase II Simon Two-Stage Multicenter Study and Pilot Pharmacodynamic Investigation of GTI 2040 in Combination With High Dose Cytarabine (HiDAC) in Refractory and Relapsed Acute Myeloid Leukemia (AML)).

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2015

At a glance

  • Drugs LOR 2040 (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jan 2011 This trial was completed in 2009, according to a Lorus Therapeutics media release
    • 14 Jun 2010 Results presented at 15th Annual Congress of the European Hematology Association (EHA), according to a Lorus Therapeutics media release.
    • 17 Feb 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top